PRLD

Prelude Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↑ 5/10
  • Value↓ 0/10
Prelude Therapeutics sales and earnings growth
PRLD Growth
Neutral
  • Revenue Y/Y↑ 73.43%
  • EPS Y/Y↑ 23.21%
  • FCF Y/Y↑ 45.62%
Prelude Therapeutics gross and profit margin trends
PRLD Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -819.60%
  • ROIC 5Y↓ -77.91%
Prelude Therapeutics net debt vs free cash flow
PRLD Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Prelude Therapeutics stock volatility is higher than the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks